ICSI Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Intracytoplasmic sperm injection (ICSI) is an advanced assisted reproductive technology (ART) technique in which a single sperm cell is selected under a high-powered inverted microscope and injected directly into the cytoplasm of a mature (metaphase II) oocyte using a fine glass microneedle. This bypasses all natural sperm-egg interaction barriers — including sperm motility, zona pellucida penetration, and acrosome reaction — and enables fertilisation to occur even with severely abnormal sperm parameters or surgically retrieved sperm.

ICSI was first performed successfully by Palermo et al. at the Vrije Universiteit Brussel in 1992 and has since become the most widely used fertilisation technique in IVF laboratories worldwide. In many countries, ICSI is now used in more than 60–70% of all ART cycles, including in many couples with no identified male factor — though this 'ICSI for all' approach remains debated in the absence of clear outcome advantage over conventional IVF insemination in normal male factor cases.

ICSI shares the same ovarian stimulation, oocyte retrieval, and embryo culture steps as conventional IVF. The critical difference lies solely in the fertilisation technique: instead of placing thousands of sperm around each egg in a culture dish (conventional IVF insemination), a single selected sperm is injected directly into each mature egg.

ICSI does not overcome all infertility barriers: the quality of the oocyte and the embryological laboratory environment remain critical determinants of successful fertilisation, blastocyst development, implantation, and live birth. Fertilisation rates of 60–80% per injected mature oocyte are typical in well-run laboratories, meaning approximately 1 in 5 injected eggs may fail to fertilise even with ICSI.

ICSI is the standard fertilisation technique for the following clinical situations:

Male Factor Infertility

• Severe oligozoospermia: Sperm concentration below 5 million/mL (WHO 2021 reference values: 16 million/mL lower reference limit). Severely reduced concentration makes standard IVF insemination unreliable; ICSI enables fertilisation with just a single viable sperm per oocyte.
• Severe asthenozoospermia: Fewer than 30% progressively motile sperm (WHO 2021 lower reference value). Extremely poor motility impairs sperm's ability to penetrate the oocyte even in standard IVF culture, making ICSI necessary.
• Severe teratozoospermia: Fewer than 4% morphologically normal sperm (WHO Kruger strict criteria). Although the Kruger threshold for ICSI recommendation has been debated, severe forms with near-zero normal forms (globozoospermia — round-headed sperm — being the most extreme) require ICSI.
• Combined severe OAT (oligoasthenoteratozoospermia): Combination of all three abnormalities; ICSI is unambiguously indicated.

Obstructive Azoospermia with Surgical Sperm Retrieval

Men with obstructive azoospermia (absent sperm in ejaculate due to physical blockage despite normal spermatogenesis) can have sperm retrieved surgically for use in ICSI:

• PESA (percutaneous epididymal sperm aspiration): Fine needle aspiration of the epididymis under local anaesthesia; appropriate for post-vasectomy azoospermia and obstructive azoospermia
• TESA (testicular sperm aspiration): Fine needle aspiration of the testis; less invasive than TESE
• TESE (testicular sperm extraction) / micro-TESE: Surgical biopsy of testicular tissue; micro-TESE uses operating microscope to identify areas of active spermatogenesis; preferred for non-obstructive azoospermia where sperm production is impaired

Surgically retrieved sperm have limited motility and cannot penetrate eggs independently; ICSI is the only fertilisation method compatible with epididymal or testicular sperm.

Non-obstructive Azoospermia (NOA)

NOA results from testicular failure (primary or secondary hypogonadism, Klinefelter syndrome, prior chemotherapy/radiotherapy, cryptorchidism). Micro-TESE retrieves sperm in approximately 40–60% of NOA cases; retrieved sperm must be used immediately or cryopreserved for ICSI. Genetic counselling is essential in NOA — Klinefelter syndrome (47,XXY) carries a 50% aneuploidy risk in embryos, making PGT-A strongly advisable.

Prior Fertilisation Failure with Conventional IVF

Couples who have experienced total or near-total fertilisation failure in a previous IVF cycle are offered ICSI in subsequent cycles, even if male parameters are apparently normal. Fertilisation failure with standard IVF suggests a sperm-oocyte interaction problem — a zona binding or fusion defect — that ICSI bypasses.

Preimplantation Genetic Testing (PGT)

When PGT-A (aneuploidy) or PGT-M (monogenic disease) is planned, ICSI is mandated to fertilise eggs. This prevents contamination of the embryo biopsy with extraneous sperm DNA that could produce erroneous genetic results — a critical accuracy requirement for PGT-M in particular.

ICSI is part of the IVF pathway; eligibility assessment for the full IVF/ICSI cycle is required before commencing treatment.

Female Partner Assessment

• Ovarian reserve: Anti-Mullerian hormone (AMH) and antral follicle count (AFC) on days 2–5 transvaginal ultrasound predict ovarian response to stimulation. AMH below 1.0 pmol/L or AFC below 4–5 indicates poor response; POSEIDON classification guides stimulation protocol for poor responders.
• Uterine cavity assessment: Transvaginal ultrasound; hysteroscopy or saline sonohysterography where submucosal fibroids, polyps, or adhesions are suspected — intrauterine pathology significantly reduces implantation rates
• Hormonal profile: FSH, LH, oestradiol, progesterone, thyroid function, prolactin on days 2–5 of the menstrual cycle
• Infectious screening: HIV, hepatitis B and C, rubella immunity, syphilis — mandatory for all ART treatment
• Genetic screening: Karyotype in women with recurrent implantation failure or recurrent miscarriage; BRCA carrier testing if clinically indicated; carrier screening for CF, SMA, fragile X

Male Partner Assessment

• Semen analysis: Two samples 2–4 weeks apart per WHO 2021 criteria; DNA fragmentation index (DFI) if high or recurrent failure — DFI above 25% (TUNEL assay) predicts reduced blastocyst development
• Karyotype and Y microdeletion testing: Recommended for azoospermia and severe oligozoospermia (sperm count below 5 million/mL)
• Cystic fibrosis mutation screening: CFTR mutations are the most common cause of obstructive azoospermia (bilateral absence of vas deferens, CBAVD); female partner must also be screened before proceeding
• Hormonal assessment: FSH, LH, testosterone, prolactin for azoospermia work-up — distinguishes obstructive (normal FSH) from non-obstructive (elevated FSH) azoospermia

Eligibility for NHS Funding (UK)

NICE Guideline NG156 recommends offering IVF/ICSI on the NHS to eligible couples. Local Clinical Commissioning Group (ICB) criteria typically include: age of female partner (usually 23–39), duration of infertility (at least 2 years of regular unprotected intercourse), BMI (18.5–30 in most centres), non-smoker status, and absence of children from current or previous relationships. NHS funding typically covers 1–3 full cycles depending on age and local policy.

ICSI follows the same structured phases as conventional IVF, with the specific ICSI fertilisation step performed in the embryology laboratory.

Phase 1: Controlled Ovarian Stimulation (COS)

The aim is to mature multiple follicles simultaneously, increasing the number of oocytes available for retrieval. Protocols vary by ovarian reserve, age, and clinical history:

• GnRH antagonist protocol (flexible or fixed): Now the predominant protocol. Daily FSH/LH injections from day 2–3 of cycle; GnRH antagonist added when leading follicle reaches 12–14 mm to prevent premature LH surge. Trigger with hCG or GnRH agonist (preferred in OHSS-risk patients) when the leading follicle reaches 17–18 mm.
• GnRH agonist long protocol: Down-regulation with GnRH agonist from the mid-luteal phase of the preceding cycle before starting stimulation. Longer protocol; still used in poor responders and specific clinical situations.
• Mild stimulation (mini-IVF): Lower dose gonadotropins or oral clomiphene with fewer oocytes retrieved; used in poor responders or women who decline standard stimulation.

Follicle monitoring by transvaginal ultrasound (and serum oestradiol) is performed every 2–3 days during stimulation (typically 10–14 days).

Phase 2: Oocyte Trigger and Retrieval

When at least 3 follicles reach 17–18 mm, final oocyte maturation is triggered with hCG (10,000 IU) or GnRH agonist (leuprorelin or buserelin). Oocyte retrieval is performed under transvaginal ultrasound guidance 34–36 hours after trigger, using a fine aspiration needle passed through the vaginal wall under sedation or general anaesthesia. Retrieved follicular fluid is immediately examined by the embryologist for oocytes; mature (MII) oocytes are isolated and cultured.

Phase 3: ICSI Fertilisation

Approximately 4–6 hours after retrieval, each mature oocyte is denuded of its surrounding granulosa cells (corona radiata) to allow injection. The embryologist uses an inverted microscope at 400x magnification with two micromanipulators:

• A holding pipette immobilises the egg with gentle suction (3 o'clock position)
• An injection pipette (approximately 6–8 micrometres inner diameter) is used to pick up a single morphologically selected sperm, immobilise it by touching the tail with the pipette tip (disrupting the tail membrane), aspirate it tail-first into the injection pipette
• The injection pipette is inserted through the zona pellucida and the oolemma (egg membrane) at the 6 o'clock position with controlled suction confirming cytoplasm entry
• The sperm and a minimal volume of culture medium are injected directly into the oocyte cytoplasm

Each mature oocyte receives one sperm injection. Fertilisation is confirmed by the presence of two pronuclei (2PN) at 16–18 hours post-injection.

Phase 4: Embryo Culture and Assessment

Fertilised embryos are cultured in individual micro-droplets or in time-lapse incubators (e.g., Embryoscope) that allow continuous morphokinetic monitoring without removing embryos from the incubator. Embryos are assessed at:

• Day 2–3: Cleavage stage (4–8 cells); scored for cell number, symmetry, and fragmentation
• Day 5–6: Blastocyst stage (inner cell mass + trophectoderm); graded by expansion, ICM quality, and trophectoderm quality (Gardner scale: e.g., 4AA is optimal)

Blastocyst culture is preferred over Day 3 transfer when multiple embryos are available — blastocysts have better implantation potential and allow improved embryo selection.

Phase 5: Embryo Transfer and Luteal Support

One or two embryos (elective single embryo transfer, eSET, is recommended to minimise twin pregnancy risks) are transferred transcervically under abdominal ultrasound guidance using a soft catheter. No anaesthesia is required. Vaginal progesterone (pessaries or gel) is prescribed from day of oocyte retrieval until 8–10 weeks of pregnancy. Pregnancy test is performed 12–14 days post-transfer.

Surplus good-quality embryos are vitrified (rapid cryopreservation) for potential future frozen embryo transfer (FET) cycles.

ICSI has transformed the treatment of male factor infertility, enabling biological parenthood for couples who previously had no realistic chance of conception.

Fertilisation Rates

ICSI achieves fertilisation rates of 60–80% per injected mature oocyte in experienced laboratories — substantially higher than the fertilisation rates achievable with conventional IVF insemination in severe male factor cases. The remaining 20–40% of injected oocytes fail to fertilise, most commonly due to oocyte aneuploidy, oocyte activation failure (particularly relevant in severe teratozoospermia and globozoospermia — where assisted oocyte activation with calcium ionophore may be required), or technical factors.

Live Birth Rates by Female Age

Live birth rates are primarily determined by female age (a reflection of oocyte quality and aneuploidy rates) rather than by the choice between ICSI and IVF insemination:

• Under 35 years: Approximately 32–38% live birth rate per egg collection cycle
• 35–37 years: Approximately 25–30% per cycle
• 38–39 years: Approximately 18–22% per cycle
• 40–42 years: Approximately 12–17% per cycle
• Over 42 years: Approximately 5–10% per cycle with own eggs (use of donor eggs substantially improves success to 40–50% regardless of recipient age)

These figures represent cumulative outcomes from human fertilisation and embryology authority (HFEA) data and international registries. Individual clinic outcomes vary and should be interpreted in the context of casemix.

Benefits Over Conventional IVF in Appropriate Indications

• Enables fertilisation in men with fewer than 100,000 total motile sperm in the ejaculate — a population where conventional IVF consistently produces very low or zero fertilisation
• The only viable option when surgical sperm retrieval (TESA/PESA/TESE) is necessary
• Required for all PGT cycles to prevent extraneous DNA contamination
• May reduce total fertilisation failure compared to conventional IVF in borderline or unexplained infertility cases

Cumulative Success with Frozen Embryo Transfer

Vitrification technology has dramatically improved frozen embryo survival rates (greater than 95% per embryo warmed). Cumulative live birth rates including all freeze-thaw cycles from a single stimulation and retrieval (one 'egg collection') are substantially higher than single fresh cycle success rates — often exceeding 50–60% in women under 37 with a good response.

ICSI is generally safe, but the ovarian stimulation component carries specific risks, and certain concerns specific to the ICSI technique itself have been raised and require counselling.

Ovarian Hyperstimulation Syndrome (OHSS)

The most important acute complication of ovarian stimulation. OHSS results from excessive ovarian response producing large numbers of follicles and elevated oestradiol, leading to vascular permeability, fluid shift from the intravascular to third compartments, ascites, haemoconcentration, and in severe cases, renal failure, thromboembolism, and respiratory compromise.

• Mild OHSS: Bloating, mild abdominal discomfort, slight weight gain — self-limiting; managed conservatively at home
• Moderate OHSS: Significant abdominal distension, nausea, vomiting, detectable ascites on ultrasound — managed with increased fluid intake and monitoring
• Severe OHSS: Tense ascites, haemoconcentration (haematocrit greater than 45%), oliguria, thromboembolic risk — requires hospitalisation, IV fluid management, and paracentesis

Risk factors: polycystic ovary syndrome (PCOS), high AFC, young age, low BMI, prior OHSS. Strategies to reduce OHSS risk include: GnRH antagonist protocol, GnRH agonist trigger (instead of hCG), lower stimulation doses, 'freeze-all' strategy (cryopreserve all embryos, defer transfer to a subsequent cycle).

Multiple Pregnancy

Transfer of more than one embryo risks twin or triplet pregnancy — the most significant health risk associated with IVF/ICSI. Twins carry substantially elevated risks of preterm birth, low birth weight, neonatal ICU admission, cerebral palsy, and maternal complications. eSET (elective single embryo transfer) in women under 37 with good-quality blastocysts available is strongly recommended to minimise this risk without significantly reducing cumulative live birth rates across freeze-thaw cycles.

Procedure-Related Risks

• Oocyte retrieval: Vaginal bleeding, pelvic infection (approximately 0.3–0.5%), inadvertent bowel or vessel injury (rare); pelvic abscess risk in women with prior endometriosis or dilated tubes (hydrosalpinx)
• ICSI mechanical injury to oocyte: A small proportion (approximately 3–5%) of injected oocytes undergo mechanical degeneration at injection — an inherent technical risk of the invasive procedure

ICSI-Specific Genetic Concerns

• Transmission of male infertility: Genetic causes of severe male factor infertility (Y chromosome microdeletions, CFTR mutations in CBAVD) are transmitted to male offspring. Male sons of men with AZFc deletions will also have azoospermia and require ICSI themselves. Genetic counselling before ICSI is essential.
• Epigenetic imprinting: Some studies have suggested a slightly elevated risk of imprinting disorders (Beckwith-Wiedemann syndrome, Angelman syndrome) in ICSI-conceived children compared to the general population, though absolute risks remain very low and overall child health outcomes from long-term follow-up studies are reassuring.
• Congenital abnormalities: Large registry studies suggest a marginally elevated risk of certain cardiac septal defects and urogenital anomalies in ICSI-conceived children compared to the general population; whether this is related to the ICSI technique or to underlying parental infertility remains debated.

ICSI treatment requires close monitoring throughout the stimulation and post-retrieval phases, with ongoing support through the two-week wait and early pregnancy.

During Stimulation

• Transvaginal ultrasound follicle tracking every 2–3 days from day 6–8 of stimulation
• Serum oestradiol monitoring every 1–2 days (in high-responders at OHSS risk)
• Daily self-administration of subcutaneous injections with clinic support available for troubleshooting

Post-retrieval and Fertilisation Feedback

• Fertilisation results communicated by the embryology team at 16–18 hours post-injection
• Embryo development updates on Day 3 and Day 5/6 (blastocyst grading)
• Embryo transfer timing decision made collaboratively based on number and quality of developing embryos

After Embryo Transfer

• Luteal phase support: vaginal progesterone commenced from retrieval day, continued until beta-hCG test (Day 12–14 post-transfer) and, if positive, until 8–10 weeks gestation
• Pregnancy test (serum beta-hCG): quantitative result at 12–14 days post-transfer; rising levels indicate early pregnancy; very high levels may prompt OHSS reassessment
• Viability ultrasound: transvaginal scan at 6–7 weeks gestation to confirm intrauterine location, fetal pole, and cardiac activity

If Cycle Is Unsuccessful

A review consultation with the specialist is arranged to discuss cycle outcome, embryology findings, and revised prognosis for future cycles. Frozen embryo transfer (FET) cycles are offered for patients with cryopreserved embryos — either in a natural cycle (monitoring ovulation) or hormonally programmed cycle (oestrogen + progesterone). FET cycles are simpler, lower-risk, and substantially cheaper than a fresh cycle.

PGT-A and PGT-M Follow-up

When preimplantation genetic testing is performed, embryo biopsy (Day 5–6 trophectoderm biopsy) results take 1–2 weeks. Only chromosomally normal (euploid) embryos are transferred in a subsequent FET cycle. PGT-A reduces miscarriage risk and may improve live birth rates per transfer — particularly valuable in women aged 35 and above or with a history of recurrent miscarriage.

ICSI treatment costs vary widely by country, clinic, and the complexity of treatment required. Understanding the full cost breakdown — including medication, monitoring, laboratory fees, and potential additional procedures — is essential for financial planning.

Approximate Costs by Region

• United Kingdom (private, 2026): A standard ICSI cycle typically costs £4,000–£6,500 including monitoring, oocyte retrieval, ICSI fertilisation, and one fresh embryo transfer. Medication costs add a further £800–£2,000 depending on ovarian reserve and protocol. Cryopreservation of surplus embryos adds £300–£500 initially and approximately £300–£500 per year for storage. PGT-A adds approximately £2,000–£3,500 for biopsy and genetic testing.
• United Kingdom (NHS): NICE NG156 recommends 3 full IVF/ICSI cycles for eligible women under 40; 1 cycle for eligible women aged 40–42. Actual NHS provision varies significantly by Integrated Care Board — many areas fund fewer cycles or impose additional eligibility criteria.
• United States: A full ICSI cycle typically costs $12,000–$20,000 before medications ($3,000–$6,000 additional). Insurance coverage varies considerably by state and employer plan; ART mandates exist in some states. Donor egg cycles cost $25,000–$40,000.
• India: Complete ICSI cycle (stimulation, retrieval, ICSI, transfer) costs approximately £1,200–£2,500 at accredited fertility centres — one of the most cost-effective destinations globally. JCI-accredited fertility hospitals in Delhi, Mumbai, Chennai, and Bangalore are popular for medical tourism.
• Spain, Czech Republic, Greece: Popular European fertility tourism destinations; ICSI cycles typically cost £3,000–£5,500 with donor eggs available where indicated

Additional Cost Factors

• Surgical sperm retrieval (TESA/PESA/micro-TESE): adds £800–£2,500 per procedure
• Embryo vitrification and annual storage fees
• Frozen embryo transfer cycles: approximately £1,000–£2,500 per FET (significantly cheaper than fresh cycles)
• Preimplantation genetic testing (PGT-A/PGT-M): biopsy, genetic analysis, and genetic counselling fees
• Sperm DNA fragmentation testing: £150–£350
• Acupuncture, nutritional supplements, and complementary therapies: optional add-ons with limited RCT evidence — couples should be aware of potential costs for unproven adjuncts

The choice between ICSI and conventional IVF insemination, and the role of adjunctive treatments, depends on the specific diagnosis and clinical context.

Conventional IVF Insemination

When male parameters are within the normal reference range (WHO 2021), conventional IVF insemination — placing 50,000–100,000 prepared motile sperm around each egg in co-culture — achieves similar or identical fertilisation rates to ICSI in randomised trials. The HFEA and ESHRE advise against routine use of ICSI in non-male-factor infertility as it does not improve live birth rates and adds cost and potential risk. Couples with non-male-factor unexplained infertility or female-factor infertility alone are generally offered conventional IVF as the first approach.

Split Insemination (ICSI + Conventional IVF)

In borderline male factor cases, some clinics split the mature oocytes — performing ICSI on half and conventional insemination on the other half. This provides comparative fertilisation data to guide future cycle decisions and may partially mitigate the risk of total fertilisation failure with either technique alone.

Physiological ICSI (PICSI)

PICSI selects sperm based on their ability to bind to hyaluronan (a component of the oocyte cumulus matrix) — a marker of sperm maturity, normal chromatin, and lower DNA fragmentation. RCT evidence (PICSI trial, Brison et al. 2023) demonstrated a significant reduction in miscarriage rate with PICSI, though no significant improvement in live birth rate. NICE does not routinely recommend PICSI but acknowledges emerging evidence.

Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)

IMSI uses ultra-high magnification (6,000x versus standard 400x) to exclude sperm with nuclear vacuoles before injection. Meta-analyses show inconsistent benefit; NICE does not recommend IMSI as a routine add-on given insufficient evidence of live birth improvement.

Oocyte Activation (Calcium Ionophore)

In cases of prior total fertilisation failure or severe teratozoospermia with globozoospermia (round-headed sperm lacking an acrosome), oocytes may fail to activate normally after ICSI. Artificial oocyte activation (AOA) using calcium ionophore (A23187 or ionomycin) applied to oocytes immediately after ICSI can rescue fertilisation in these specific circumstances. AOA is indicated where oocyte activation deficiency is confirmed; not recommended routinely.

Donor Sperm IUI or IVF/ICSI

In men with very severe non-obstructive azoospermia where micro-TESE fails, or in men who decline surgical retrieval, donor sperm insemination (IUI) or donor sperm IVF/ICSI are effective alternatives enabling the female partner to carry a biological pregnancy.